Back to Authors

Kurland, John F.

https://orcid.org/0000-0003-0863-2486

A5048077180 | I4210150756

Mayo Clinic

AstraZeneca (United States)

Citations 3

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Future Oncology | September 6, 2023 | Volume: 19 | Issue: 38 | Pages: 2505-2516

10.2217/fon-2023-0486 | PMID 37671641

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

NEJM Evidence | June 6, 2022 | Volume: 1 | Issue: 8 | Pages: No page available

10.1056/evidoa2100070 | PMID 38319892

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4502-4502

10.1200/jco.2016.34.15_suppl.4502